493 related articles for article (PubMed ID: 27936479)
21. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; He Y; Swiatek-de Lange M; Morgenstern D; Chan HL
Hepatol Commun; 2022 Apr; 6(4):679-691. PubMed ID: 34796691
[TBL] [Abstract][Full Text] [Related]
22. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.
Beudeker BJB; Fu S; Balderramo D; Mattos AZ; Carrera E; Diaz J; Prieto J; Banales J; Vogel A; Arrese M; Oliveira J; Groothuismink ZMA; van Oord G; Hansen BE; de Man RA; Debes JD; Boonstra A
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708457
[TBL] [Abstract][Full Text] [Related]
23. Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems.
Attallah AM; Omran MM; Attallah AA; Abdelrazek MA; Farid K; El-Dosoky I
Int J Clin Oncol; 2017 Apr; 22(2):332-339. PubMed ID: 27864623
[TBL] [Abstract][Full Text] [Related]
24. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma.
Chen VL; Sharma P
Clin Liver Dis; 2020 Nov; 24(4):577-590. PubMed ID: 33012446
[TBL] [Abstract][Full Text] [Related]
25. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
[TBL] [Abstract][Full Text] [Related]
26. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
28. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.
Grazi GL; Mazziotti A; Legnani C; Jovine E; Miniero R; Gallucci A; Palareti G; Gozzetti G
Liver Transpl Surg; 1995 Jul; 1(4):249-55. PubMed ID: 9346575
[TBL] [Abstract][Full Text] [Related]
29. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
[TBL] [Abstract][Full Text] [Related]
30. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma.
Chalasani NP; Porter K; Bhattacharya A; Book AJ; Neis BM; Xiong KM; Ramasubramanian TS; Edwards DK; Chen I; Johnson S; Roberts LR; Kisiel JB; Reddy KR; Singal AG; Olson MC; Bruinsma JJ
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):173-182.e7. PubMed ID: 34391922
[TBL] [Abstract][Full Text] [Related]
31. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
32. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
[TBL] [Abstract][Full Text] [Related]
33. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
34. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.
Chon YE; Choi GH; Lee MH; Kim SU; Kim DY; Ahn SH; Kim KS; Choi JS; Han KH; Chon CY; Park JY
Int J Cancer; 2012 Nov; 131(10):2332-41. PubMed ID: 22362471
[TBL] [Abstract][Full Text] [Related]
35. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
38. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.
Chaiteerakij R; Zhang X; Addissie BD; Mohamed EA; Harmsen WS; Theobald PJ; Peters BE; Balsanek JG; Ward MM; Giama NH; Moser CD; Oseini AM; Umeda N; Venkatesh S; Harnois DM; Charlton MR; Yamada H; Satomura S; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
Liver Transpl; 2015 May; 21(5):599-606. PubMed ID: 25789635
[TBL] [Abstract][Full Text] [Related]
39. GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
Qiao W; Li J; Xiong Y; Zheng J; Jin R; Hu C
J Cancer Res Clin Oncol; 2024 May; 150(5):241. PubMed ID: 38713414
[TBL] [Abstract][Full Text] [Related]
40. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.
Toyoda H; Kikuchi K; Tsuruta Y; Hiraoka A; Tsuji K; Tanaka J
Nephrol Dial Transplant; 2021 May; 36(6):1097-1103. PubMed ID: 33009910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
